Skip to main content

Table 1 Baseline patient characteristics by treatment

From: Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study

Variables Abatacept
n = 1496
Other bDMARDs
n = 3490
csDMARDs
n = 1520
Age, years, mean (SD) 61.5 (12.8) 60.9 (12.9) 63.3 (12.9)
Female 85.5 83.6 80.9
Education, years, mean (SD) 13.8 (2.3) 13.9 (2.3) 13.6 (2.4)
White 94.1 93.5 93.0
Disease duration, years, mean (SD) 16.6 (12.2) 16.6 (12.1) 15.3 (13.8)
Rheumatic Disease Comorbidity Index score (0–9), mean (SD) 2.1 (1.7) 2.0 (1.6) 2.0 (1.6)
Body mass index, kg/m2, mean (SD) 29.0 (7.3) 28.8 (7.1) 29.1 (7.3)
History of smoking 42.9 45.2 48.2
Hypertension 38.5 38.1 39.0
Diabetes 12.2 11.9 13.7
History of cancer 26.5 25.7 28.1
HAQ-DI score (0–3), mean (SD) 1.3 (0.7) 1.2 (0.7) 1.1 (0.7)
Pain score (0–10), mean (SD) 5.6 (2.7) 4.9 (2.8) 4.5 (2.8)
Patient global score (0–10), mean (SD) 4.9 (2.5) 4.4 (2.5) 4.2 (2.5)
Number of prior csDMARDs, mean (SD) 2.9 (1.9) 2.7 (1.8) 2.2 (1.5)
Number of prior bDMARDs, mean (SD) 1.7 (1.2) 1.0 (1.1) 0.2 (0.6)
 0 15.2 41.9 89.3
 1 34.6 30.3 6.9
 2–3 44.3 24.5 3.4
 ≥ 4 5.9 3.3 0.5
Concurrent methotrexate 51.7 55.0 45.7
Concurrent other non-MTX csDMARDs 21.0 21.0 37.0
Concurrent glucocorticoid 43.0 34.0 31.0
 < 7.5 mg/day 63.7 64.9 65.7
 7.5–< 15 mg/day 25.6 25.1 22.2
 ≥ 15 mg/day 10.8 10.1 12.1
Concurrent NSAID 41.3 42.8 44.5
  1. The values are presented as % unless indicated otherwise. Baseline is treatment start date; patients who switched treatment during the study could be allocated to more than one group
  2. As prednisone dose equivalents
  3. bDMARD biologic disease-modifying antirheumatic drug, csDMARD conventional synthetic disease-modifying antirheumatic drug, HAQ-DI Health Assessment Questionnaire-Disability Index, MTX methotrexate, NSAID nonsteroidal anti-inflammatory drug, SD standard deviation
\